Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Published:2014-09-27 Issue:16 Volume:74 Page:1691-1696
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Conteduca Vincenza¹,Burgio Salvatore Luca¹,Menna Cecilia¹,Carretta Elisa²,Rossi Lorena¹,Bianchi Emanuela¹,Masini Carla³,Amadori Dino¹,De Giorgi Ugo¹

Affiliation:

1. Department of Medical Oncology; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)-IRCCS; Meldola Italy

2. Department of Biostatistics and Clinical Trials; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)-IRCCS; Meldola Italy

3. Pharmacy Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)-IRCCS; Meldola Italy

Publisher

Wiley

Subject

Urology,Oncology

Reference27 articles.

1. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion;Harris;Nat Clin Pract Urol,2009

2. Mechanisms underlying the development of androgen-independent prostate cancer;Pienta;Clin Cancer Res,2006

3. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis;Yuan;Oncogene,2014

4. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

5. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study;Scher;Lancet,2010

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis;Cells;2024-08-22

2. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers;Cancer Treatment Reviews;2024-04

3. Small Cell/Neuroendocrine Prostate Cancer: A Rare Treatment-Resistant Variant Presenting as Acute Onset Severe Back Pain;Cureus;2024-01-16

4. Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer;Journal of Clinical Medicine;2023-05-09

5. PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC;Thoracic Cancer;2023-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3